Let the ASCO games begin. It looks like the ASCO floodgates have busted wide open, based on yesterdayGÇÖs biotechGÇÖs wild ride.-á The momentum all started last week with GenentechGÇÖs (DNA) release of-á positive phase III data on its new anti-angiogenesis drug.-á The instigator yesterday was ImClone (IMCLE), with a news release before the opening bell.-á The company stated it would receive a $6 million milestone payment from its European partner Merck KGaA related to the upcoming release of phase III
The post Several Important Meetings Coming Soon — Here’s What I’m Looking At appeared first on TradingMarkets.com.